Observational studyJournal of atherosclerosis and thrombosis2020
Decreased Appendicular Skeletal Muscle Mass is Associated with Poor Outcomes after ST-Segment Elevation Myocardial Infarction.
Observational study in Journal of atherosclerosis and thrombosis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Risk factors of stroke-related sarcopenia: a systematic review and meta-analysis.Frontiers in aging · 2025Pooled it
- Sarcopenia is linked to higher levels of B-type natriuretic peptide and its N-terminal fragment in heart failure: a systematic review and meta-analysis.European geriatric medicine · 2024Pooled it
- A systematic review and meta-analysis of the association between sarcopenia and myocardial infarction.BMC geriatrics · 2023Pooled it
- Sarcopenia predicts adverse outcomes in an elderly population with coronary artery disease: a systematic review and meta-analysis.BMC geriatrics · 2021Pooled it
- Sarcopenia and Cardiogeriatrics: The Links Between Skeletal Muscle Decline and Cardiovascular Aging.Nutrients · 2025Review
- Myosteatosis predicts the prognosis of patients with ST-elevation myocardial infarction who undergo emergency percutaneous coronary intervention.Frontiers in endocrinology · 2025Article
- Impact of Low-Density Lipoprotein Cholesterol Levels at Acute Coronary Syndrome Admission on Long-Term Clinical Outcomes.Journal of atherosclerosis and thrombosis · 2024Article
- Cross-sectional and longitudinal association between atrial fibrillation and sarcopenia: Findings from the Korean frailty and aging cohort study.Journal of cachexia, sarcopenia and muscle · 2024Article
- Is sarcopenia an associated factor of increased administration of specific medications in patients with heart failure? A systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2024Review
- Impact of Handgrip Strength on Clinical Outcomes after Percutaneous Coronary Intervention.Journal of atherosclerosis and thrombosis · 2023Observational
- Relationship Between Number of Cardiac Rehabilitation Exercise Training Sessions, Muscle Mass, and Cardiorespiratory Fitness in Rural Elderly Patients with Coronary Artery Disease.Journal of multidisciplinary healthcare · 2023Article
- Serum transthyretin and aminotransferases are associated with lean mass in people with coronary heart disease: Further insights from the CARE-CR study.Frontiers in medicine · 2023Article
- Sarcopenia and Frailty in Heart Failure: Is There a Biomarker Signature?Current heart failure reports · 2022Review
- SARC-F Is a Predictor of Longer LOS and Hospital Readmission in Hospitalized Patients after a Cardiovascular Event.Nutrients · 2022Article
- Sarcopenia-derived exosomal micro-RNA 16-5p disturbs cardio-repair via a pro-apoptotic mechanism in myocardial infarction in mice.Scientific reports · 2021Article
- Skeletal muscle mass is associated with glycemic variability in patients with ST-segment elevation myocardial infarction.Heart and vessels · 2021Observational
- Relationship Between Sarcopenia and Cardiovascular Diseases in the Elderly: An Overview.Frontiers in cardiovascular medicine · 2021Review
- Loss of Skeletal Muscle Mass and Poor Prognosis in Patients with ST-Segment Elevation Myocardial Infarction: Underling Mechanisms and Therapeutic Strategies.Journal of atherosclerosis and thrombosis · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe importance of sarcopenia in cardiovascular diseases has been recently demonstrated. This study aims to examine whether skeletal muscle mass (SMM), an important component of sarcopenia, is associated with an increased risk of poor outcome in patients after ST-segment elevation myocardial infarction (STEMI).
methodsWe measured SMM in 387 patients with STEMI using dual-energy X-ray absorptiometry. Patients were divided into low- and high-appendicular skeletal mass index (ASMI: appendicular SMM divided by height squared (kg/m
resultsLow-ASMI group was older and had a more complex coronary lesion, a lower left ventricular ejection fraction, and a higher prevalence of Killip classification ≥ 2 than high-ASMI group. During a median follow-up of 33 months, the event rate was significantly higher in low-ASMI group than in high-ASMI group (24.7% vs 13.4%, log-rank p=0.001). Even after adjustment for patients' background, low ASMI was independently associated with the high risk of primary composite events (adjusted hazard ratio 2.06, 95% confidence interval 1.01- 4.19, p=0.04). In the subgroup analyses of male patients (n=315), the optimal cutoff point of ASMI for predicting primary composite outcome was 6.75 kg/m
conclusionsLow ASMI is independently associated with poor outcome in patients with STEMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.